CANY
ALNY icon

Caxton Associates (New York)’s Alnylam Pharmaceuticals ALNY Stock Holding History

Caxton Associates (New York)’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,431
Closed -$508K – 306
2020
Q2 		$508K Buy
+3,431
New +$463K 0.04% 137

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Caxton Associates (New York)'s ALNY Position: Q3 2020 in Review

Caxton Associates (New York) sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2020, closing a stake of 3,431 shares — an estimated $508K sold.

Caxton Associates (New York) first reported a position in ALNY in Q2 2020 and held it in 1 quarter. The position peaked at $508K in Q2 2020. 356 funds tracked by Wall St. Rank hold ALNY as of Q3 2020.

  • Caxton Associates (New York) reported no remaining Alnylam Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Caxton Associates (New York) sold 3,431 Alnylam Pharmaceuticals shares in Q3 2020, an estimated $508K.
  • Caxton Associates (New York) first reported a position in Alnylam Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Caxton Associates (New York)'s Alnylam Pharmaceuticals position peaked at $508K in Q2 2020.
  • 356 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2020.

Based on Caxton Associates (New York)'s 13F filing for Q3 2020, filed 16 Nov 2020.